What exactly changed in the Deutsche Bank note on Feb 12, 2026?

Deutsche Bank maintained a **Buy** rating and raised its Novartis price target to **EUR 135** from **EUR 125** on February 12, 2026. The note left the Buy recommendation unchanged while increasing the valuation target, signaling sustained analyst confidence.

How should I interpret the NVS analyst rating for my portfolio?

A maintained Buy and higher price target suggests analysts expect steady growth or pipeline wins. Use the NVS analyst rating to adjust position size, review valuation assumptions, and align holdings with risk tolerance and investment horizon.

Does the Deutsche Bank action mean a big move in the stock?

Not necessarily. The February 12, 2026 note caused a small immediate move of **-0.38% ($-0.61)**. The maintained Buy and modest target rise often prompt revaluation over weeks, not instant large swings.

Where can I read the analyst note and live quotes for NVS?

The Deutsche Bank update is summarized by TheFly and is available here [source](https://thefly.com/permalinks/entry.php/id4291986/3461286394/NVS-Novartis-price-target-raised-by-EUR--at-Deutsche-Bank). Live quotes and broader coverage are available on Novartis’s CNBC page [source](https://www.cnbccom

Analyst Ratings

Deutsche Bank Maintains Buy on Novartis AG (NVS) Feb 2026, PT €135

ByHuzaifa Zahoor February 13, 2026February 13, 2026

Deutsche Bank on February 12, 2026 maintained a Buy rating on Novartis AG (NVS) and raised its price target to EUR 135 from EUR 125. This NVS analyst rating action kept the firm’s positive view while nudging valuation expectations higher. The update signals confidence in Novartis’s pipeline and near-term earnings resilience. Investors should note the precise move and the reported price change since the note of -0.38% ($-0.61).